Super‐Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription‐Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer
2024

Targeting Gallbladder Cancer with SOX9 and TCF7L2

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Yan Siyuan, Liu Zhaonan, Wang Teng, Sui Yi, Wu Xiangsong, Shen Jiayi, Pu Peng, Yang Yang, Wu Sizhong, Qiu Shimei, Wang Ziyi, Jiang Xiaoqing, Feng Feiling, Li Guoqiang, Liu FaTao, Zhao Chaoxian, Liu Ke, Feng Jiayi, Li Maolan, Man Kwan, Wang Chaochen, Tang Yujie, Liu Yingbin

Primary Institution: Shanghai Jiao Tong University School of Medicine

Hypothesis

Can SOX9 and TCF7L2 form a core regulatory circuitry that drives oncogenic super-enhancer reprogramming in gallbladder cancer?

Conclusion

SOX9 and TCF7L2 are crucial for gallbladder cancer progression and represent potential therapeutic targets.

Supporting Evidence

  • SOX9 and TCF7L2 co-occupy each other's super-enhancer regions.
  • Patients with higher levels of SOX9 and TCF7L2 in their tumors have worse prognosis.
  • SOX9/TCF7L2 double-high gallbladder cancer models are sensitive to CDK7 inhibition therapy.

Takeaway

This study found that two proteins, SOX9 and TCF7L2, work together in gallbladder cancer cells, making them grow faster and more aggressively, but also making them vulnerable to certain treatments.

Methodology

The study used CUT&Tag and ChIP-seq to analyze the genomic distribution of H3K27ac in gallbladder cancer samples and cell lines.

Limitations

The study primarily focused on a limited number of gallbladder cancer samples and cell lines.

Participant Demographics

The study included 8 primary gallbladder cancer samples and 2 benign gallbladder samples.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202406448

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication